Part of the debate – in the House of Commons at 1:31 pm on 7th June 2018.

Alert me about debates like this

Photo of Nick Herbert Nick Herbert Conservative, Arundel and South Downs 1:31 pm, 7th June 2018

I agree that some companies are willing to take a non-commercial view, such as Johnson & Johnson and Osaka Pharmaceuticals, but many other major pharmaceutical companies are not developing new TB tools because there is no commercial incentive. Therefore, we do need that partnership funding to make this happen.

I would argue that there are three powerful reasons for us to act: a humanitarian reason because of the number of deaths, an economic reason because of the cost to the global economy of not doing so, and a global health security reason because of the risk of drug resistance.